Synthetic antigens for the detection of antibodies to hepatitis C virus

ABSTRACT

Peptide sequences are provided which are capable of mimicking proteins encoded by HCV for use as reagents for screening of blood and blood products for prior exposure to HCV. The peptides are at least 5 amino acids long and can be used in various specific assays for the detection of antibodies to HCV, for the detection of HCV antigens, or as immunogens.

The implementation of systematic testing for hepatitis B virus (HBV) has been instrumental in eliminating this virus from the blood supply. Nevertheless, a significant number of post-transfusion hepatitis (PFM) cases still occur. These cases are generally attributable to non-A, non-B hepatitis (NANBH) virus(es), the diagnosis of which is usually made by exclusion of other viral markers.

The etiological agent responsible for a large proportion of these cases has recently been cloned (Choo, Q-L et al. Science (1988) 244:359-362) 15 and a first-generation antibody test developed (Kuo, G. et al. Science (1989) 244:362-364). The agent has been identified as a positive-stranded RNA virus, and the sequence of its genome has been partially determined. Studies suggest that this virus, referred to subsequently as hepatitis C virus (HCV), may be related to flaviviruses and pestiviruses. A portion of the genome of an HCV isolated from a chimpanzee (HCV_(CDC/CHI)) is disclosed in EPO 88310922.5. The coding sequences disclosed in this document do not include sequences originating from the 5′-end of the viral genome which code for putative structural-proteins. Recently however, sequences derived from this region of the HCV genome have been published (Okamoto, H. et, al., Japan J. Exp. Med. 60:167-177, 1990.). The amino acid sequences encoded by the Japanese clone HC-J1 were combined with the HCV_(CDC/CHI) sequences in a region where the two sequences overlap to generate the composite sequence depicted in FIG. 1. Specifically, the two sequences were so joined at glycine₄₅₁. It should be emphasized that the numbering system used for the HCV amino acid sequence is not intended to be absolute since the existence of variant HCV strains harboring deletions or insertions is highly probable. Sequences corresponding to the 5′ end of the HCV genome have also recently been disclosed in EPO 90302866.0.

In order to detect potential carriers of HCV, it is necessary to have access to large amounts of viral proteins. In the case of HCV, there is currently no known method for culturing the virus, which precludes the lo use of virus-infected cultures as a source of viral antigens. The current first-generation antibody test makes use of a fusion protein containing a sequence of 363 amino acids encoded by the HCV genome. It was found that antibodies to this protein could be detected in 75 to 85% of chronic NANBH patients. In contrast, only approximately 15% of those is patients who were in the acute phase of the disease, had antibodies which recognized this fusion protein (Kuo, G. et al. Science (1989) 244:362-364). The absence of suitable confirmatory tests, however, makes it difficult to verify these statistics. The seeming similarity between the HCV genome and that of flaviviruses makes it possible to predict the location of epitopes which are likely to be of diagnostic value. An analysis of the HCV genome reveals the presence of a continuous long open reading frame. Viral RNA is presumably translated into a long polyprotein which is subsequently cleaved by cellular and/or viral proteases. By analogy with, for example, Dengue virus, the viral structural proteins are presumed to be derived from the amino-terminal third of the viral polyprotein. At the present time, the precise sites at which the polyprotein is cleaved can only be surmised. Nevertheless, the structural proteins are likely to contain epitopes which would be useful for diagnostic purposes, both for the detection of antibodies as well as for raising antibodies which could subsequently be used for the detection of viral antigens. Similarly, domains of nonstructural proteins are also expected to contain epitopes of diagnostic value, even though these proteins are not found as structural components of virus particles.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the amino acid sequence of the composite HCV_(Hc-J1/CDC/CHI)

FIG. 2 shows the antibody binding to individual peptides and various mixtures in an ELISA assay

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

It is known that RNA viruses frequently exhibit a high rate of spontaneous mutation and, as such, it is to be expected that no two HCV isolates will be completely identical, even when derived from the same individual. For the purpose of this disclosure, a virus is considered to be the same or equivalent to HCV if it exhibits a global homology of 60 percent or more with the HCV_(Hc-J1/CDC/CHI) composite sequence at the nucleic acid level and 70 percent at the amino acid level.

Peptides are described which immunologically mimic proteins encoded by HCV. In order to accommodate strain-to-strain variations in sequence, conservative as well as non-conservative amino acid substitutions may be made. These will generally account for less than 35 percent of a specific sequence. It may be desirable in cases where a peptide corresponds to a region in the HCV polypeptide which is highly polymorphic, to vary one or more of the amino acids so as to better mimic the different epitopes of different viral strains.

The peptides of interest will include at least five, sometimes six, sometimes eight, sometimes twelve, usually fewer than about fifty, more usually fewer than about thirty-five, and preferably fewer than about twenty-five amino acids included within the sequence encoded by the HCV genome. In each instance, the peptide will preferably be as small as possible while still maintaining substantially all of the sensitivity of the larger peptide. It may also be desirable in certain instances to join two or more peptides together in one peptide structure.

It should be understood that the peptides described need not be identical to any particular HCV sequence, so long as the subject compounds are capable of providing for immunological competition with at least one strain of HCV. The peptides may therefore be subject to insertions, deletions, and conservative or non-conservative amino acid substitutions where such changes might provide for certain advantages in their use.

Substitutions which are considered conservative are those in which the chemical nature of the substitute is similar to that of the original amino acid. Combinations of amino acids which could be considered conservative are Gly, Ala; Asp, Glu; Asn, Gln; Val, Ile, Leu; Ser, Thr, Lys, Arg; and Phe, Tyr.

Furthermore, additional amino acids or chemical groups may be added to the amino- or carboxyl terminus for the purpose of creating a “linker arm” by, which the peptide can conveniently be attached to a carrier. The linker arm will be at least one amino acid and may be as many as 60 amineo acids but will most frequently be 1 to 10 amino acids. The nature of the attachment to a solid phase or carrier need not be covalent.

Natural amino acids such as cysteine, lysine, tyrosine, glutamic acid, or aspartic acid may be added to either the amino- or carboxyl terminus to provide functional groups for coupling to a solid phase or a carrier. However, other chemical groups such as, for example, biotin and thioglycolic acid, may be added to the termini which will endow the peptides with desired chemical or physical properties. The termini of the peptides may also be modified, for example, by N-terminal acetylation or terminal carboxy-amidation. The peptides of interest are described in relation to the composite amino acid sequence shown in FIG. 1. The amino acid sequences are given in the conventional and universally accepted three-letter code. In addition to the amino acids shown, other groups are defined as follows: Y is, for example, NH₂, one or more N-terminal amino acids, or other moieties added to facilitate coupling. Y may itself be modified by, for example, acetylation. Z is a bond, (an) amino acid(s), or (a) chemical group(s) which may be used for linking. X is intended to represent OH, NH₂, or a linkage involving either of these two groups.

Peptide I corresponds to amino acids 1 to 20 and has the following amino acid sequences: Y-Met-Ser-Thr-Ile-Pro-Lys-Pro-Gln-Arg-Lys- (I) Thr-Lys-Arg-Asn-Thr-Asn-Arg-Arg-Pro-Gln-Z- X.

Peptide II corresponds to amino acids 7 to 26 and has the amino acid sequence: Y-Pro-Gln-Arg-Lys-Thr-Lys-Arg-Asn-Thr-Asn- (II) Arg-Arg-Pro-Gln-Asp-Val-Lys-Phe-Pro-Gly-Z- X.

Of particular interest is the oligopeptide IIA: Y-Gln-Arg-Lys-Thr-Lys-Arg-Asn-Thr-Asn-Arg- (IIA) Arg-Z-X.

Peptide III corresponds to amino acids 13 to 32 and has the sequence: Y-Arg-Asn-Thr-Asn-Arg-Arg-Pro-Gln-Asp-Val- (III) Lys-Phe-Pro-Gly-Gly-Gly-Gln-Ile-Val-Gly-Z- X.

Peptide IV corresponds to amino acid 37 to 56 and has the sequences: Y-Leu-Pro-Arg-Arg-Gly-Pro-Arg-Leu-Gly-Val- (IV) Arg-Ala-Thr-Arg-Lys-Thr-Ser-Glu-Arg-Ser-Z- X.

Peptide V corresponds to amino acids 49 to 68 and has the sequence: Y-Thr-Arg-Lys-Thr-Ser-Glu-Arg-Ser-Gln-Pro- (V) Arg-Gly-Arg-Arg-Gln-Pro-Ile-Pro-Lys-Val-Z- X.

Peptide VI corresponds to amino acid 61 to 80 and has the following sequence: Y-Arg-Arg-Gln-Pro-Ile-Pro-Lys-Val-Arg-Arg- (VI) Pro-Glu-Gly-Arg-Thr-Trp-Ala-Gln-Pro-Gly-Z- X.

Peptide VII corresponds to amino acids 73 to 92 and has the sequence: Y-Gly-Arg-Thr-Trp-Ala-Gln-Pro-Gly-Tyr-Pro- (VII) Trp-Pro-Leu-Tyr-Gly-Asn-Glu-Gly-Cys-Gly-Z- X.

Peptide VIII corresponds to amino acids 1688 to 1707 and has the sequence: Y-Leu-Ser-Gly-Lys-Pro-Ala-Ile-Ile-Pro-Asp- (VIII) Arg-Glu-Val-Leu-Tyr-Arg-Glu-Phe-Asp-Glu-Z- X.

Peptide IX corresponds to amino acids 1694 to 1713 and has the sequence: Y-Ile-Ile-Pro-Asp-Arg-Glu-Val-Leu-Tyr-Arg- (IX) Glu-Phe-Asp-Glu-Met-Glu-Glu-Cys-Ser-Gln-Z- X.

Peptide X corresponds to ammo acids 1706 to 1725 and has the sequence: Y-Asp-Glu-Met-Glu-Glu-Cys-Ser-Gln-His-Leu- (X) Pro-Tyr-Ile-Glu-Gln-Gly-Met-Met-Leu-Ala-Z- X.

Peptide XI corresponds to amino acids 1712 to 1731 and has the sequence: Y-Ser-Gln-His-Leu-Pro-Tyr-Ile-Glu-Gln-Gly- (XI) Met-Met-Leu-Ala-Glu-Gln-Phe-Lys-Gln-Lys-Z- X.

Peptide XII corresponds to amino acids 1718 to 1737 and has the sequence: Y-Ile-Glu-Gln-Gly-Met-Met-Leu-Ala-Glu-Gln- (XII) Phe-Lys-Gln-Lys-Ala-Leu-Gly-Leu-Leu-Gln-Z- X.

Peptide XIII corresponds to amino acids 1724 to 1743 and has the sequence: Y-Leu-Ala-Glu-Gln-Phe-Lys-Gln-Lys-Ala-Leu- (XIII) Gly-Leu-Leu-Gln-Thr-Ala-Ser-Arg-Gln-Ala-Z- X.

Peptide XIV corresponds to amino acids 1730 to 1749 and has the sequence: Y-Gln-Lys-Ala-Leu-Gly-Leu-Leu-Gln-Thr-Ala- (XIV) Ser-Arg-Gln-Ala-Glu-Val-Ile-Ala-Pro-Ala-Z- X.

Peptide XV corresponds to amino acids 2263 to 2282 and has the sequence: Y-Glu-Asp-Glu-Arg-Glu-Ile-Ser-Val-Pro-Ala- (XV) Glu-Ile-Leu-Arg-Lys-Ser-Arg-Arg-Phe-Ala-Z- X.

Peptide XVI corresponds to amino acids 2275 to 2294 and has the sequence: Y-Leu-Arg-Lys-Ser-Arg-Arg-Phe-Ala-Gln-Ala- (XVI) Leu-Pro-Val-Trp-Ala-Arg-Pro-Asp-Tyr-Asn-Z- X.

Peptide XVII corresponds to amino acids 2287 to 2306 and has the sequence: Y-Val-Trp-Ala-Arg-Pro-Asp-Tyr-Asn-Pro-Pro- (XVII) Leu-Val-Glu-Thr-Trp-Lys-Lys-Pro-Asp-Tyr-Z- X.

Peptide XVIII corresponds to amino acids 2299 to 2318 and has the sequence: Y-Glu-Thr-Trp-Lys-Lys-Pro-Asp-Tyr-Glu-Pro- (XVIII) Pro-Val-Val-His-Gly-Cys-Pro-Leu-Pro-Pro-Z- X.

Peptide XIX corresponds to amino acids 2311 to 2330 and has the sequence: Y-Val-His-Gly-Cys-Pro-Leu-Pro-Pro-Pro-Lys- (XIX) Ser-Pro-Pro-Val-Pro-Pro-Pro-Arg-Lys-Lys-Z- X.

Of particular interest is the use of the mercapto-group of cysteines or thioglycolic acids used for acylating terminal amino groups for cyclizing the peptides or coupling two peptides together. The cyclization or coupling may occur via a single bond or may be accomplished using thiol-specific reagents to form a molecular bridge.

The peptides may be coupled to a soluble carrier for the purpose of either raising antibodies or facilitating the adsorption of the peptides to a solid phase. The nature of the carrier should be such that it has a molecular weight greater than 5000 and should not be recognized by antibodies in human serum. Generally, the carrier will be ⁻a protein. Proteins which are frequently used as carriers are keyhole limpet hemocyanin, bovine gamma globulin bovine serum albumin, and poly-L-lysine.

There are many well described techniques for coupling peptides to carriers. The linkage may occur at the N-terminus, C-terminus or at an internal site in the peptide. The peptide may also be derivatized for coupling. Detailed descriptions of a wide variety of coupling procedures are given, for example, in Van Regenmortel, N .H. V., Briand, J. P., Muller, S., and Plaué, S., Laboratory Techniques in Biochemistry and Molecular Biology, Vol. 19, Synthetic Polypeptides as Antigens, Elsevier Press, Amsterdam, N.Y., Oxford, 1988.

The peptides may also be synthesized directly on an oligo-lysine core in which both the alpha as well as the epsilon-amino groups of lysines are used as growth points for the peptides. The number of lysines comprising the core is preferably 3 or 7. Additionally, a cysteine may be included near or at the C-terminus of the complex to facilitate the formation of homo- or heterodimers. The use of this technique has been amply illustrated for hepatitis B antigens (Tam, J. P., and Lu, Y-A., Proc. Natl. Acad. Sci. USA (1989) 86:9084-9088) as well as for a variety of other antigens (see Tam, J. P., Multiple Antigen Peptide System: A Novel Design for Synthetic Peptide Vaccine and Immnunoassay, in Synthetic Peptides, Approaches to Biological Problems, Tam, J. P., and Kaiser, E. T., ed. Alan R. Liss Inc., New York, 1989).

Depending on their intended use, the peptides may be either labeled or unlabeled. Labels which may be employed may be of any type, such as enzymatic, chemical, fluorescent, luminescent, or radioactive. In addition, the peptides may be modified for binding to surfaces or solid phases, such as, for example, microtiter plates, nylon membranes, glass or plastic beads, and chromatographic supports such as cellulose, silica, or agarose. The methods by which peptides can be attached or bound to solid support or surface are well known to those versed in the art.

Of particular interest is the use of mixtures of peptides for the detection of antibodies specific for hepatitis C virus. Mixtures of peptides which are considered particularly advantageous are:

-   -   A. II, III, V, IX, and XVIII     -   B. I, II, V, IX, XI, XVI, and XVIII     -   C. II, III, IV, V, VIII, XI, XVI, and XVIII     -   D. II, IX, and XVIII     -   E. II, III, IV, and V     -   F. VIII, IX, XI, XIII, and XIV     -   G. XV, XVI, XVII, XVIII, and XIX

Antibodies which recognize the peptides can be detected in a variety of ways. A preferred method of detection is the enzyme-linked immunosorbant assay (ELISA) in which a peptide or mixture of peptides is bound to a solid support. In most cases, this will be a microtiter plate but may in principle be any sort of insoluble solid phase. A suitable dilution or dilutions of serum or other body fluid to be tested is brought into contact with the solid phase to which the peptide is bound. The incubation is carried out for a time necessary to allow the binding reaction to occur. Subsequently, unbound components are removed by washing the solid phase. The detection of immune complexes is achieved using antibodies which specifically bind to human immunoglobulins, and which have been labeled with an enzyme, preferably but not limited to either horseradish peroxidase, alkaline phosphatase, or beta-galactosidase, which is capable of converting a colorless or nearly colorless substrate or co-substrate into a highly colored product or a product capable of forming a colored complex with a chromogen. Alternatively, the detection system may employ an enzyme which, in the presence of the proper substrate(s), emits light. The amount of product formed is detected either visually, spectrophotometrically, electrochemically, or luminometrically, and is compared to a similarly treated control. The detection system may also employ radioactively labeled antibodies, in which case the amount of immune complex is quantified by scintillation counting or gamma counting.

Other detection systems which may be used include those based on the use of protein A derived from Staphylococcis aureus Cowan strain I, protein G from group C Staphylococcus sp. (strain 26RP66), or systems which make use of the high affinity biotin-avidin or streptavidin binding reaction

Antibodies raised to carrier-bound peptides can also be used in conjunction with labeled peptides for the detection of antibodies present in serum or other body fluids by competition assay. In this case, antibodies raised to carrier-bound peptides are attached to a solid support which may be, for example, a plastic bead or a plastic tube. Labeled peptide is then mixed with suitable dilutions of the fluid to be tested and this mixture is subsequently brought into contact with the antibody bound to the solid support After a suitable incubation period, the solid support is washed and the amount of labeled peptide is quantified. A reduction in the amount of label bound to the solid support is indicative of the presence of antibodies in the original sample. By the same token, the peptide may also be bound to the solid support. Labeled antibody may then be allowed to compete with antibody present in the sample under conditions in which the amount of peptide is limiting. As in the previous example, a reduction in the measured signal is indicative of the presence of antibodies in the sample tested.

Another preferred method of antibody detection is the homogeneous immunoassay. There are many possible variations in the design of such assays. By way of example, numerous possible configurations for homogeneous enzyme immunoassays and methods by which they may be performed are given in Tijssen, P., Practice and Theory of Enzyme Immunoassays, Elsevier Press, Amersham, Oxford, N.Y. 1985. s Detection systems which may be employed include those based on enzyme channeling, bioluminescence, allosteric activation and allosteric inhibition. Methods employing liposome-entrapped enzymes or coenzymes may also be used (see Pinnaduwage, P. and Huang, L., Clin. Chem. (1988) 34/2: 268-272, and Ullman, E. F. et al., Clin. Chem. (1987) 33/9: 1579-1584 for examples).

The synthesis of the peptides can be achieved in solution or on a solid support. Synthesis protocols generally employ the use t-butyloxycarbonyl- or or 9-fluorenylmethoxy-carbonyl-protected activated amino acids. The procedures for carrying out the syntheses, the types of side-chain protection, and the cleavage methods are amply described in, for example, Stewart and Young, Solid Phase Peptide Synthesis, 2nd Edition, Pierce Chemical Company, 1984; and Atherton and Sheppard, Solid Phase Peptide Synthesis, IRL Press, 1989.

Experimental

I. Peptide Synthesis

All of the peptides described were synthesized on Pepsyn K polyamide-Kieselguhr resin (Milligen, Novato, Calif.) which had been functionalized with ethylenediamine and onto which the acid-labile linker 4(alpha-Fmoc-amino-2′, 4′-dimethoxybenzyl) phenoxyacetic acid had been coupled (Rink, Tetrahedron Lett. (1987) 28:3787). t-Butyl-based side-chain protection and Fmoc alpha-amino-protection was used. The guanidino-group of arginine was protected by the 2,2,7,8-pentamethylchroman-6-sulfonyl moiety. The imidazole group of histidine was protected by either t-Boc or trityl and the sulfhydryl group of cysteine was protected by a trityl group. Couplings were carried out using performed O-pentafluorophenyl esters except in the case of arginine where diisopropylcarbodiimide-mediated hydroxybenzotriazole ester formation was employed. Except for peptide I, all peptides were N-acetylated using acetic anhydride. All syntheses were carried out on a Milligen 9050 PepSynthesizer (Movato, Calif.) using continuous flow procedures. Following cleavage with trifluoroacetic acid in the presence of scavengers and extraction with diethylether, all peptides were analyzed by C₁₈-reverse phase chromatography.

II. Detection of Antibodies to Hepatitis C Virus

A. Use of peptides Bound to a Nylon Membrane

Peptides were dissolved in a suitable buffer to make a concentrated stock solution which was then further diluted in phosphate-buffered saline (PBS) or sodium carbonate buffer, pH 9.6 to make working solutions. The peptides were applied as lines on a nylon membrane (Pall, Portsmouth, United Kingdom), after which the membrane was treated with casein to block unoccupied binding sites. The membrane was subsequently cut into strips perpendicular to the direction of the peptide lines. Each strip was then incubated with a serum sample diluted 1 to 100, obtained from an HCV-infected individual. Antibody binding was detected by incubating the strips with goat anti-human immunoglobulin antibodies conjugated to the enzyme alkaline phosphatase. After removing unbound conjugate by washing, a substrate solution containing 5-bromo4chloro-3-indolylphosphate and nitro blue tetrazolium was added.

Positive reactions are visible as colored lines corresponding to the 5 positions of the peptides which are specifically recognized. The reaction patterns of thirty-six different sera are tabulated in Table 1. The results shown in Table 1 are further summarized in Table 2.

B. Use of Peptides in an Enzyme-Linked Immunosorbent Assay (ELISA)

Peptide stock solutions were diluted in sodium carbonate buffer, pH 9.6 and used to coat microtiter plates at a peptide concentration of 2 micrograms per milliliter. A mixture consisting of peptides II, III, V, IX, and XVIII was also used to coat plates. Following coating, the plates were blocked with casein. Fifteen HCV-antibody-positive sera and control sera from seven uninfected blood donors were diluted 1 to 20 and incubated in wells of the peptide-coated plates. Antibody binding was detected by incubating the plates with goat anti-human immunoglobulin antibodies conjugated to the enzyme horseradish peroxidase. Following removal of unbound conjugate by washing, a solution containing H₂O₂ and 3,3′, 5, 5′-tetramethylbenzidine was added. Reactions were stopped after a suitable interval by addition of sulfuric acid. Positive reactions gave rise to a yellow color which was quantified using a conventional microtiter plate reader. The results of these determinations are tabulated in Table 3. To correct for any aspecific binding which could be attributable to the physical or chemical properties of the peptides themselves, a cut-off value was determined for each peptide individually. This cut-off absorbance value was calculated as the average optical density of the negative samples plus 0.200. Samples giving absorbance values higher than the cut-off values are considered positive. The results for the fifteen positive serum samples are further summarized in Table 4.

While it is evident that some of the peptides are recognized by a large percentage of sera from HCV-infected individuals, it is also clear that no single peptide is recognized by all sera In contrast, the peptide mixture was recognized by all fifteen sera and, for six of the fifteen sera, the optical densities obtained were equal to or higher than those obtained for any of the peptides individually. These results serve to illustrate the advantages of using mixtures of peptides for the detection of anti-HCV antibodies.

C. Binding of Antibodies in Sera from HCV-Infected Patients to Various Individual Peptides and Peptide Mixtures in an ELISA

Five peptides were used individually and in, seven different combinations to coat microtiter plates. The plates were subsequently incubated with dilutions of fifteen HCV antibody-positive sera in order to evaluate the relative merits of using mixtures as compared to individual peptides for antibody detection The mixtures used and the results obtained are shown in FIG. 2.

In general, the mixtures functioned better than individual peptides. This was particularly evident for mixture 12 (peptides I, III, V, IX and XVIII) which was recognized by all twelve of the sera tested. These results underscore the advantages of using mixtures of peptides in diagnostic tests for the detection of antibodies to HCV.

D. Use of a Mixture of Peptides in an ELISA Assay for the Detection of Anti-HCV Antibodies

A mixture of peptides II, III, V, IX, and XVIII was prepared and used to coat microtiter plates according to the same procedure used to test the individual peptides. A total of forty-nine sera were tested from patients with clinically diagnosed but undifferentiated chronic non A non B hepatitis as well as forty-nine sera from healthy blood donors. Detection of antibody binding was accomplished using goat anti-human immunoglobulin antibodies conjugated to horseradish peroxidase. The resulting optical density values are given in Table 5. These results indicate that the mixture of peptides is not recognized by antibodies in sera from healthy donors (0/49 reactives) but is recognized by a large proportion (41/49, or 84%) of the sera from patients with chronic NANBH. These results demonstrate that the peptides described can be used effectively as mixtures for the diagnosis of HCV infection.

E. Detection of Anti-HCV Antibodies in Sera from patients with Acute NANB Infection using Individual Peptides Bound to Nylon Membranes and a Mixture of Peptides in an ELISA Assay, and Comparison with a Commercially Available Kit

Peptides were applied to nylon membranes or mixed and used to coat microtiter plates as previously described. The peptide mixture consisted of peptides II, III, V, IX, and XVIII. Sera obtained from twenty-nine patients with acute non-A, non-B hepatitis were then tested for the presence of antibodies to hepatitis C virus. These same sera were also evaluated using a commercially available kit (Ortho, Emeryville, Calif., USA).

The results of this comparative study are given in Table 6. In order to be able to compare the peptide-based ELISA with the commercially available kit, the results for both tests are also expressed as signal to noise ratios (S/N) which were calculated by dividing the measured optical density obtained for each sample by the cut-off value. A signal-to-noise ratio greater or equal to 1.0 is taken to represent a positive reaction. For the commercially available kit, the cut-off value was calculated according to the manufacturer's instructions. The cut-off value for the peptide-based ELISA was calculated as the average optical density of five negative is samples plus 0.200.

The scale used to evaluate antibody recognition of nylon-bound peptides was the same as that given in Table 1. Of the twenty-nine samples tested, twenty-five (86%) were positive in the peptide-based ELISA and recognized one or more nylon-bound peptides. In contrast, only fourteen of the twenty-nine sera scored positive in the commercially available ELISA These results serve to illustrate the advantages of using peptide mixtures for the detection of anti-HIV antibodies as well as the need to include in the mixtures peptides which contain amino acid sequences derived from different regions of the HCV polyprotein. TABLE 1 Recognition of peptides bound to nylon membranes by sera from persons infected by HCV. Serum PEPTIDE nr. I II III IV V VI VII VIII IX X XI XII XIII XIV XV XVI XVII XVIII XIX 1 3 1 1 0.5 2 2 1 1 2 0.5 1 2 2 1 3 1 0.5 2 1 0.5 2 0.5 1 0.5 4 1 6 2 1 0.5 2 7 0.5 1 2 1 0.5 3 2 2 1 1 2 0.5 1 1 8 0.5 1 3 1 1 1 1 2 1 1 1 1 0.5 10 1 0.5 3 1 1 0.5 2 2 2 2 13 0.5 0.5 2 0.5 1 1 0.5 0.5 15 0.5 2 1 0.5 1 0.5 16 2 1 0.5 0.5 1 0.5 2 0.5 1 2 2 1 2 18 1 1 3 0.5 2 0.5 1 0.5 23 0.5 1 1 0.5 1 0.5 0.5 0.5 24 1 0.5 2 1 0.5 0.5 0.5 2 1 25 1 0.5 2 0.5 0.5 2 1 1 2 26 1 0.5 27 0.5 0.5 1 3 2 1 2 1 0.5 29 0.5 3 2 1 1 0.5 2 1 1 1 2 2 1 1 1 30 0.5 0.5 1 1 0.5 31 1 0.5 0.5 0.5 0.5 32 1 2 1 0.5 1 1 33 0.5 1 0.5 0.5 34 1 1 1 3 1 1 1 0.5 35 1 1 2 1 1 1 0.5 36 1 2 1 1 37 1 1 44 1 2 1 0.5 2 0.5 46 0.5 2 0.5 0.5 0.5 2 47 0.5 0.5 0.5 1 1 1 48 1 2 2 0.5 2 0.5 1 1 1 0.5 49 1 1 0.5 0.5 0.5 0.5 0.5 0.5 1 50 1 2 1 2 0.5 1 1 1 1 1 0.5 0.5 51 2 0.5 0.5 0.5 1 1 0.5 52 2 0.5 0.5 0.5 54 2 0.5 0.5 1 0.5 1 1 1 1 1 1 56 ND ND ND ND ND ND ND 2 0.5 1 2 1 Blank: no reaction; 0.5: weakly positive; 1: clearly positive; 2: strong reaction; 3: intense reaction; ND: not determined

TABLE 2 Summary of antibody binding to nylon-bound HCV peptides by sera from infected patients. Peptide No. reactive sera % reactive sera I 13/35 37 II 22/35 63 III 27/35 77 IV 24/35 69 V 14/35 40 VI 11/35 31 VII 11/35 31 VIII 19/36 53 IX  9/36 25 X 17/36 47 XI 15/36 42 XII  1/36 3 XIII 13/36 36 XIV  7/36 19 XV  9/36 25 XVI 20/36 56 XVII 14/36 39 XVIII 14/36 39 XIX  8/36 22

TABLE 3 Comparison of Individual Peptides in an ELISA Assay for the Detection of Antibodies to HCV. sample peptide ident I II III IV V VI VII VIII IX X XI XII XIII XIV XV XVI XVII XVIII XIX  1 0.786 1.119 1.284 0.265 0.042 0.04 0.05 0.571 0.659 0.048 0.04 0.043 0.068 0.044 0.041 1.063 0.956 1.383 1.346  2 0.044 0.039 0.11 0.041 0.037 0.038 0.039 0.479 0.78 0.169 0.563 0.039 0.042 0.515 0.039 0.64 0.319 0.154 0.49  3 0.815 0.944 0.825 0.399 0.654 0.487 0.32 0.705 0.965 0.468 0.668 0.041 0.093 0.341 0.043 0.292 0.038 0.046 0.038  7 1.122 1.23 0.588 0.682 0.659 0.182 0.107 0.907 1.42 0.663 0.646 0.041 0.235 0.068 0.575 0.042 0.041 0.872 1.271  8 1.155 1.159 1.2 0.508 1.272 0.433 0.623 0.61 0.863 0.752 1.175 0.046 0.42 0.102 0.068 0.552 0.671 0.417 0.058 10 1.089 1.236 1.083 0.044 0.508 0.042 0.073 1.49 1.529 0.689 0.834 0.041 0.044 0.314 0.793 0.886 0.037 1.335 1.356 11 0.048 0.051 0.476 0.052 0.119 0.039 0.1 0.634 0.711 0.199 0.967 0.125 0.454 0.088 0.111 0.274 0.093 0.838 0.065 15 0.224 0.602 0.813 0.093 0.068 0.077 0.147 0.807 1.225 0.315 0.688 0.046 0.154 0.202 0.065 0.372 0.097 0.155 0.077 23 0.62 0.8 0.924 0.568 0.759 0.442 0.683 0.089 0.121 0.422 0.896 0.041 0.049 0.101 0.068 0.311 0.038 0.052 0.05 24 1.042 1.132 1.026 0.518 0.916 0.302 0.253 1.013 1.364 0.236 0.397 0.054 0.123 0.076 0.051 0.418 0.053 0.1 0.085 49 0.624 0.73 0.884 0.171 0.372 0.055 0.04 0.084 0.064 0.209 0.731 0.044 0.113 0.039 0.044 0.299 0.038 0.192 0.041 13 0.76 0.857 0.815 0.087 0.422 0.098 0.045 0.473 0.489 0.529 0.735 0.043 0.044 0.186 0.043 0.086 0.037 0.066 0.04 31 0.84 1.114 0.445 0.672 0.046 0.041 0.042 0.184 0.15 0.255 0.69 0.041 0.04 0.061 0.136 0.292 0.038 0.224 0.501 47 1.303 1.53 1.236 0.751 0.83 0.629 0.073 0.545 0.739 0.044 0.041 0.041 0.041 0.498 0.04 0.268 0.042 1.288 1.206 56 1.169 1.301 1.364 1.269 1.374 0.85 1.066 1.45 1.523 0.079 1.069 0.058 0.568 0.038 0.039 0.218 0.036 0.087 0.039 bd A 28 0.054 0.043 0.139 0.045 0.135 0.042 0.041 0.086 0.115 0.044 0.042 0.044 0.052 0.043 0.043 0.307 0.042 0.045 0.061 bd A 169 0.041 0.042 0.134 0.044 0.038 0.04 0.041 0.061 0.07 0.043 0.042 0.041 0.04 0.041 0.041 0.255 0.038 0.056 0.042 bd A 170 0.042 0.044 0.117 0.04 0.036 0.04 0.04 0.081 0.05 0.04 0.039 0.04 0.038 0.038 0.144 0.292 0.036 0.058 0.039 bd A 171 0.041 0.046 0.148 0.043 0.037 0.045 0.045 0.077 0.065 0.043 0.041 0.043 0.039 0.04 0.045 0.286 0.037 0.05 0.04 bd A 166 0.047 0.046 0.124 0.044 0.038 0.042 0.041 0.056 0.066 0.041 0.041 0.042 0.04 0.041 0.041 0.207 0.039 0.046 0.041 bd A 165 0.041 0.046 0.123 0.043 0.035 0.051 0.042 0.051 0.091 0.041 0.04 0.042 0.039 0.043 0.039 0.253 0.034 0.06 0.098 AVG 0.044 0.045 0.131 0.043 0.053 0.043 0.042 0.069 0.076 0.042 0.041 0.042 0.041 0.041 0.059 0.267 0.038 0.053 0.054 STD 0.005 0.002 0.011 0.002 0.037 0.004 0.002 0.013 0.021 0.001 0.001 0.001 0.005 0.002 0.038 0.033 0.002 0.006 0.021 cut off 0.109 0.101 0.214 0.099 0.214 0.105 0.098 0.158 0.189 0.095 0.094 0.095 0.106 0.097 0.223 0.416 0.084 0.121 0.167

TABLE 4 Summary of antibody-binding to individual peptides in an ELISA assay. Peptide No. reactive sera % reactive sera I 13 87 II 13 87 III 14 93 IV 10 67 V 10 67 VI 7 47 VII 8 53 VIII 13 87 IX 12 80 X 13 87 XI 13 87 XII 1 7 XIII 7 47 XIV 8 53 XV 2 13 XVI 5 33 XVII 4 27 XVIII 10 67 XIX 6 40

TABLE 5 Use of a peptide mixture for the detection of antibodies to HCV in sera from chronic NANBH patients and comparison to sera from healthy blood donors. Chronic NANB Sera Control Sera Serum nr. Optical Density Serum nr. Optical Density 101 0.041 1 0.049 102 1.387 2 0.047 103 1.578 3 0.049 104 1.804 4 0.046 105 1.393 5 0.049 107 1.604 6 0.045 108 1.148 7 0.043 109 1.714 8 0.053 110 1.692 9 0.049 112 0.919 10 0.047 113 1.454 11 0.060 114 0.936 12 0.044 115 0.041 13 0.049 116 1.636 14 0.051 118 1.242 15 0.056 119 1.568 16 0.050 120 1.290 17 0.049 121 1.541 18 0.055 122 1.422 19 0.054 123 1.493 20 0.058 124 1.666 21 0.050 125 1.644 22 0.044 126 1.409 23 0.043 127 1.625 24 0.045 128 1.061 25 0.046 129 1.553 26 0.049 130 1.709 27 0.050 131 0.041 28 0.047 132 0.044 29 0.050 133 1.648 30 0.053 134 0.043 31 0.051 135 1.268 32 0.053 136 1.480 33 0.055 138 0.628 34 0.064 139 0.042 35 0.063 140 0.040 36 0.057 141 0.039 38 0.048 142 1.659 39 0.045 143 1.457 40 0.046 144 0.722 41 0.046 145 1.256 42 0.051 146 0.373 43 0.057 147 1.732 44 0.050 148 1.089 45 0.050 149 1.606 46 0.045 150 1.725 47 0.041 151 1.449 48 0.064 154 1.639 49 0.040 155 1.775 50 0.036

TABLE 6 Comparison of anti-HCV antibody detection by nylon-bound peptides, a peptide-based ELISA, and a commercially available kit. Nylon-bound peptides Optical density Optical density Serum nr. I III IV V VI VIII XI XIV XV XVI XVIII Peptide ELISA S/N Commercial ELISA S/N 191 0 0 0 0 0 0 0 0 0 0 0 0.045 0.18 0.295 0.47 192 0 0 0 0 0 0 0 0 0 0 0 0.042 0.17 0.289 0.46 193 0 0 0 0 0 0 0 0 0 0 0 0.039 0.16 0.197 0.32 194 0 0 0 0 0 0 0 0 0 0 0 0.044 0.18 0.183 0.29 195 1 2 2 3 0 0 0.5 0.5 1 3 1 1.692 6.77 3.000* 4.82* 196 1 2 1 2 0.5 0.5 0.5 0.5 0.5 2 0 1.569 6.28 0.386 0.62 197 1 2 1 2 0 0.5 0.5 0.5 1 2 0 1.523 6.09 0.447 0.72 198 1 2 2 2 0 0 0 0 1 2 0 1.578 6.31 0.354 0.57 211 0.5 1 0.5 0.5 0 2 2 0 2 0 1 1.606 6.42 3.000* 4.82* 213 0 0 0 1 0 0 0 0 0 0 0 0.369 1.48 0.127 0.20 214 0 0 0 1 0 0 0 0 0 0 0 0.444 1.78 0.101 0.16 215 0 0 0 1 0 0 0 0 0 0 0 0.637 2.55 0.101 0.16 216 0 0 0 0.5 0 0 0 0 0 0 0 0.812 3.25 0.092 0.15 217 0 0 0 1 0 0 0 0 0 0 0 1.320 5.28 0.875 1.40 219 0.5 1 1 2 1 0.5 1 0 0.5 0.5 1 1.547 6.19 3.000* 4.82* 220 0.5 1 1 2 1 0.5 1 0 0.5 0.5 1 1.536 6.14 3.000* 4.82* 221 0 0 0 0.5 0 0 0 0 0 0 0 1.428 5.71 0.327 0.52 222 1 1 1 1 0 0 2 0.5 0.5 0 0 1.362 5.45 3.000* 4.82* 223 1 1 1 1 0 0 3 0.5. 0.5 0 0 1.316 5.26 3.000* 4.82* 224 1 1 2 1 0 0.5 3 0.5 0.5 0 0 1.304 5.22 3.000* 4.82* 225 0 0 0 0 0 0.5 0.5 0.5 0 0 2 1.178 4.71 2.398 3.85 226 0.5 0 0 0 0. 2 3 2 0.5 0.5 3 1.286 5.14 5.000* 4.82* 227 0 0 0 0 0 2 2 0.5 0.5 0.5 2 1.335 5.34 3.000* 4.82* 228 0.5 0 0.5 0.5 0 2 2 2 0 0 2 1.400 5.60 3.000* 4.82* 234 0.5 0.5 0 0.5 0 0 3 1 3 1 3 1.481 5.92 3.000* 4.82* 235 0 0 0 0.5 0 0 0 0 0 0 0 0.351 1.40 0.257 0.41 236 0 0 0 0.5 0 0 0 0 0 0 0 0.475 1.90 0.245 0.39 237 0 0 0 1 0 0 0 0 0 0 0 1.134 4.54 0.351 0.56 238 0 0 0 1 0 1 1 0 0 0 0 1.096 4.38 1.074 1.72 Cut-off: 0.250 Cut-off: 0.623 0: no reaction; 0.5: weakly positive; 1: clearly positive; 2: strong reaction; 3: intense reaction; *O.D. exceeded 3.0000 and was out of range. The values given are therefore minimum values. 

1-25. (Canceled)
 26. A kit for the detection of anti-hepatitis C virus antibodies in a body fluid sample, comprising: at least one epitope selected from the group consisting of: (a) at least 5 to at most 20 amino acids located in the region consisting of amino acids 1688 to 1707 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (b) at least 5 to at most 20 amino acids located in the region consisting of amino acids 1694 to 1713 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (c) at least 5 to at most 20 amino acids located in the region consisting of amino acids 1706 to 1725 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (d) at least 5 to at most 20 amino acids located in the region consisting of amino acids 1712 to 1731 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (e) at least 5 to at most 12 amino acids located in the region consisting of amino acids 1718 to 1737 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (f) at least 5 to at most 20 amino acids located in the region consisting of amino acids 1724 to 1743 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (g) at least 5 to at most 12 amino acids located in the region consisting of amino acids 1730 to 1749 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (h) at least 5 to at most 20 amino acids located in the region consisting of amino acids 2287 to 2306 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (i) at least 5 to at most 20 amino acids located in the region consisting of amino acids 2299 to 2318 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (j) at least 5 to at most 20 amino acids located in the region consisting of amino acids 2311 to 2330 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (k) at least 5 to at most 20 amino acids located in the region consisting of amino acids 7 to 26 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (m) at least 5 to at most 20 amino acids located in the region consisting of amino acids 13 to 32 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, and (n) at least 5 to at most 20 amino acids located in the region consisting of amino acids 49 to 68 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV; and a means for detecting an immunological complex formed between said epitope and said antibodies.
 27. The kit of claim 26, comprising a collection of at least two epitopes selected from the group consisting of (a), (b), (c), (d), (e) and (g).
 28. The kit of claim 27, comprising a collection of epitopes (a), (b), (c), (d), (e) and (g).
 29. The kit of claim 26, comprising a collection of at least two epitopes selected from the group consisting of (a), (b), (c), (d), (e) and (g) and at least two epitopes selected from the group consisting of (k), (m) and (n).
 30. The kit of claim 29, comprising a collection of epitopes selected from the group consisting of (a), (b), (c), (d), (e), (g), (k), (m) and (n).
 31. The kit of claim 26, comprising a collection of at least two epitopes selected from the group consisting of (a), (b), (c), (d), (e) and (g) and at least two epitopes selected from the group consisting of (k), (m) and (n), and at least two epitopes selected from the group consisting of (h), (i) and (j).
 32. The kit of claim 31, comprising a collection of epitopes selected from the group consisting of (a), (b), (c), (d), (e), (g), (k), (m), (n), (h), (i) and (j).
 33. The kit of claim 26, comprising a collection of at least two epitopes selected from the group consisting of (b), (c) and (d), and an epitope (m), and at least two epitopes selected from the group consisting of (h), (i) and (j).
 34. The kit of claim 33, comprising a collection of epitopes selected from the group consisting of (b), (c), (d), (m), (h), (i) and (j).
 35. The kit according to any one of claims 26-34 wherein said epitopes are independently produced by recombinant expression or chemical synthesis.
 36. The kit according to any one of claims 27-32 wherein said epitopes are produced by recombinant expression or chemical synthesis.
 37. The kit according to any one of claims 33-34 wherein at least one of said epitopes are produced by chemical synthesis.
 38. The kit of claim 26, comprising a collection of epitopes selected from the group consisting of (k), (m), (n), (b), and (i).
 39. The kit of claim 26, comprising a collection of epitopes selected from the group consisting of (k), (n), (b), (d) and (i).
 40. The kit of claim 26, comprising a collection of epitopes selected from the group consisting of (k), (m), (n), (a), (d) and (i).
 41. The kit of claim 26, comprising a collection of epitopes selected from the group consisting of (k), (b) and (i).
 42. The kit of claim 26, comprising a collection of epitopes selected from the group consisting of (k), (m) and (n).
 43. The kit of claim 26, comprising a collection of epitopes selected from the group consisting of (a), (b), (d) and (i).
 44. The kit of claim 26, comprising a collection of epitopes selected from the group consisting of (h), (i) and (j).
 45. The kit of claim 26, wherein said epitope is selected from the group consisting of (b), (i) and (m).
 46. The kit according to any one of claims 38-45 wherein said epitopes are independently produced by recombinant expression or chemical synthesis.
 47. A device for detecting anti-hepatitis C virus antibodies, comprising: (i) an isolated body fluid sample comprising said anti-hepatitis C virus antibodies, (ii) at least one epitope selected from the group consisting of: (a) at least 5 to at most 20 amino acids located in the region consisting of amino acids 1688 to 1707 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (b) at least 5 to at most 20 amino acids located in the region consisting of amino acids 1694 to 1713 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (c) at least 5 to at most 20 amino acids located in the region consisting of amino acids 1706 to 1725 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (d) at least 5 to at most 20 amino acids located in the region consisting of amino acids 1712 to 1731 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (e) at least 5 to at most 12 amino acids located in the region consisting of amino acids 1718 to 1737 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (f) at least 5 to at most 20 amino acids located in the region consisting of amino acids 1724 to 1743 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (g) at least 5 to at most 12 amino acids located in the region consisting of amino acids 1730 to 1749 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (h) at least 5 to at most 20 amino acids located in the region consisting of amino acids 2287 to 2306 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (i) at least 5 to at most 20 amino acids located in the region consisting of amino acids 2299 to 2318 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (j) at least 5 to at most 20 amino acids located in the region consisting of amino acids 2311 to 2330 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (k) at least 5 to at most 20 amino acids located in the region consisting of amino acids 7 to 26 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, (m) at least 5 to at most 20 amino acids located in the region consisting of amino acids 13 to 32 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV, and (n) at least 5 to at most 20 amino acids located in the region consisting of amino acids 49 to 68 of the HCV polyprotein of an HCV isolate wherein said epitope is capable of providing for immunological competition with at least one strain of HCV; wherein said at least one epitope is bound to an anti-hepatitis C virus antibody contained in said body sample in the form of an immunological complex.
 48. An immunological complex comprising an epitope of any of claims 27 and 45 or a collection of epitopes of any of claims 28-34 and 38-44, and a an anti-hepatitis C virus antibody contained in an isolated body fluid sample.
 49. A device for detecting anti-hepatitis C virus antibodies, comprising: (i) an isolated body fluid sample comprising said anti-hepatitis C virus antibodies, and (ii) at least one epitope collection of any of claims 28-34 and 38-44, wherein at least one epitope of said at least one epitope collection is bound to an anti-hepatitis C virus antibody contained in said body sample in the form of an immunological complex.
 50. A method for the detection of antibodies to hepatitis C virus present in a body fluid sample comprising the steps of: (a) contacting a body fluid sample of a person to be diagnosed with at least one epitope of any of claims 27 and 45 or a collection of epitopes of any of claims 28-34 and 38-44, and (b) detecting an immunological complex formed between antibodies in said body fluid sample and said at least one epitope or an epitope of said collection of epitopes, as an indication of the presence of antibodies to hepatitis C virus in said body fluid sample.
 51. The kit of any one of claims 26-34 and 38-44, wherein said at least one epitope or combination of epitopes are bound to a nylon membrane or microtiter plate.
 52. The kit of claim 51 wherein said at least one epitope or combination of epitopes are indirectly bound to said nylon membrane or microtiter plate.
 53. The immunological complex of claim 48 bound to a nylon membrane or microtiter plate.
 54. A combination of hepatitis C viral (HCV) epitopes comprising (a) a first HCV epitope comprising at least 5 amino acids from at least one first domain selected from the group consisting of the amino acids 1-20, 7-26, 8-18,13-32, 37-56, 49-68, 61-80 and 73-92 of the HCV polyprotein; and (b) a second HCV epitope comprising at least 5 amino acids from at least one second domain selected from the group consisting of amino acids 1688-1707, 1694-1713, 1706-1725, 1712-1731, 1718-1737, 1724-1743, 1730-1749, 2263-2282, 2275-2294, 2287-2306, 2299-2318, and 2311-2330 of the HCV polyprotein.
 55. A combination of hepatitis C viral (HCV) epitopes comprising (a) a first HCV epitope comprising at least 5 amino acids from at least one first domain selected from the group consisting of the amino acids 1-20, 7-26, 8-18, 13-32, 37-56, 49-68, 61-80 and 73-92 of the HCV polyprotein; and (b) a second HCV epitope comprising at least 5 amino acids from at least one second domain selected from the group consisting of amino acids 1688-1707, 1694-1713, 1706-1725, 1712-1731, 1718-1737, 1724-1743 and 1730-1749 of the HCV polyprotein, and (c) a third HCV epitope comprising at least 5 amino acids from at least one third domain selected from the group consisting of amino acids 2263-2282, 2275-2294, 2287-2306, 2299-2318, and 2311-2330 of the HCV polyprotein.
 56. A combination of claim 54 or 55 wherein said first domain is selected from the group consisting of amino acids 7-26, 13-32, and 37-56, 49-68 of the HCV polyprotein.
 57. A combination of claim 54 wherein said second domain is selected from the group consisting of amino acids 1688-1707, 1694-1713, 1706-1725, 1712-1731, 1718-1737, 1724-1743, 1730-1749, 2287-2306, 2299-2318, and 2311-2330 of the HCV polyprotein
 58. A combination of claim 55 wherein said second domain is selected from the group consisting of amino acids 1688-1707, 1694-1713, 1706-1725, 1712-1731, 1718-1737, 1724-1743, and 1730-1749, of the HCV polyprotein and said third domain is selected from the group consisting of amino acids 2287-2306, 2299-2318, and 2311-2330 of the HCV polyprotein.
 59. A combination according to claim 54, 55, 57, or 58, wherein said HCV epitopes are individually produced by recombinant expression or chemical synthesis.
 60. A combination according to claim 54, 55, 57, or 58, wherein the combination is in the form of a fusion polypeptide.
 61. A combination according to claim 54, 55, 57, or 58, wherein said epitopes are bound to a solid surface.
 62. A combination according to claims 54, 55, 57, or 58, wherein the combination is packaged into a kit further comprising control reagents for detecting antibodies to hepatitis C virus (HCV) in a mammalian body component suspected of containing said antibodies.
 63. A method of designing a kit for detection of anti-hepatitis C virus antibodies in a body fluid sample, comprising selecting at least one epitope of claim 26 and combining said at least one epitope with a support suitable for detecting said antibodies bound to said epitope.
 64. A combination according to claim 56, wherein said HCV epitopes are individually produced by recombinant expression or chemical synthesis.
 65. A combination according to claim 56, wherein the combination is in the form of a fusion polypeptide.
 66. A combination according to claim 56, wherein said epitopes are bound to a solid surface.
 67. A combination according to claim 56, wherein the combination is packaged into a kit further comprising control reagents for detecting antibodies to hepatitis C virus (HCV) in a mammalian body component suspected of containing said antibodies. 